Three things to know:
1. Dr. Sherman is a board-certified orthopedic sports medicine surgeon at Columbia-based Missouri Orthopaedic Institute. He is one of 15 primary investigators in the U.S. conducting the FDA investigational device exemption study of the Agili-C implant.
2. The Agili-C implant is a cell-free implant made of inorganic sea coral exoskeleton. It is designed to be used for a variety of cartilage defects.
3. Patients are randomly assigned to either one of the traditional surgical options — microfracture or debridement — or to receive the new implant.
“Often in studies like this one, we can enroll only a very strict sub-set of young, active patients with a single, isolated cartilage defect,” said Dr. Sherman. “In reality, that’s not the typical patient we see every day. This implant is different because it’s medically indicated for a wide range of situations including patients with multiple cartilage defects and even those with mild-moderate osteoarthritis.”
More articles on biologics:
CollPlant names new board chairman: 4 insights
Ortho RTi releases results of 2 regenerative medicine studies
California neuroscience institute joins regenerative medicine clinical trial: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
